Akari Therapeutics announces $5.5 mln private placement offering
[출처/시간] Briefing.com - 8:40 AM ET, 05/21/2026 With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.The Company entered into definitive purchase agreements with the investors for the issuance and sale of 1,470,588 unregistered American Depository Shares, or prefunded warrants in lieu thereof, and unregistered Series H
[출처/시간] Briefing.com - 8:40 AM ET, 05/21/2026
With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.The Company entered into definitive purchase agreements with the investors for the issuance and sale of 1,470,588 unregistered American Depository Shares, or prefunded warrants in lieu thereof, and unregistered Series H Warrants, Series I Warrants and Series J Warrants. The ADSs were priced at $3.74 per ADS.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
